“Retirement Secret” Showed 995% Gain Last Time We Shared It

Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.

Find out why right here (and see what you can do to get in too with just a few dollars).

Pierre Legault Biography and Net Worth

Director of Bicycle Therapeutics

Pierre Legault CPA serves as Independent Director of the Company. Mr. Legault also serves on the board of Artios Pharma (Chairman), Bicycle Therapeutics (Chairman), Poxel Pharmaceuticals (Chairman), Clementia Pharmaceuticals and Urovant Sciences. Previously, he served on the board of Armo BioSciences, Iroko Pharmaceuticals, Tobira Therapeutics, NPS Pharmaceuticals, Forest Laboratories, Cyclacel Pharmaceuticals, Eckerd Pharmacy, Regado Biosciences, NephroGenex and several others. Mr. Legault served as Chairman of NephroGenex, a biopharmaceutical company, from 2012 through 2013, and as Chief Executive Officer from 2014 through 2016, as Chief Executive Officer of Prosidion from 2010 through 2012, and Executive Vice President, Chief Financial Officer, and Treasurer of OSI Pharmaceuticals from 2009 through 2010. His prior senior executive experience also includes serving as President of Eckerd Pharmacy and as Executive Vice President and Chief Administrative Officer of Rite Aid Corporation. He also held several senior positions with Sanofi-Aventis and predecessor companies, including President of Worldwide Dermatology Operations. Mr. Legault studied at McGill University, HEC Montreal and Harvard Business School. He holds an M.B.A., BAA, CA, CPA and Six Sigma Green Belt diplomas.

What is Pierre Legault's net worth?: The estimated net worth of Pierre Legault is at least $720,640.00 as of January 12th, 2023. Legault owns 32,000 shares of Bicycle Therapeutics stock worth more than $720,640 as of April 26th. This net worth estimate does not reflect any other assets that Legault may own. Learn More about Pierre Legault's net worth.
How do I contact Pierre Legault?: The corporate mailing address for Legault and other Bicycle Therapeutics executives is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. Bicycle Therapeutics can also be reached via phone at 441223261503 and via email at [email protected]. Learn More on Pierre Legault's contact information.
Has Pierre Legault been buying or selling shares of Bicycle Therapeutics?: Pierre Legault has not been actively trading shares of Bicycle Therapeutics over the course of the past ninety days. Most recently, Pierre Legault sold 44,537 shares of the business's stock in a transaction on Tuesday, December 21st. The shares were sold at an average price of $57.11, for a transaction totalling $2,543,508.07. Learn More on Pierre Legault's trading history.
Who are Bicycle Therapeutics' active insiders?: Bicycle Therapeutics' insider roster includes Stephen Alexander (SVP), Kate Bingham (Director), Nigel Crockett (Insider), Lee Kalowski (CFO), Nicholas Keen (Insider), Kevin Lee (CEO), and Pierre Legault (Director). Learn More on Bicycle Therapeutics' active insiders.
Are insiders buying or selling shares of Bicycle Therapeutics?: In the last twelve months, insiders at the sold shares 16 times. They sold a total of 21,846 shares worth more than $438,909.08. The most recent insider tranaction occured on April, 11th when insider Michael Charles Ferguso Hannay sold 257 shares worth more than $5,779.93. Insiders at Bicycle Therapeutics own 10.2% of the company. Learn More about insider trades at Bicycle Therapeutics.
Information on this page was last updated on 4/11/2024.

Pierre Legault Insider Trading History at Bicycle Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/21/2021	Sell	44,537	$57.11	$2,543,508.07
4/8/2021	Sell	24,838	$31.71	$787,612.98	24,838
4/5/2021	Sell	162	$31.07	$5,033.34	162
3/17/2021	Sell	7,784	$29.00	$225,736.00	7,784
3/12/2021	Sell	2,216	$29.00	$64,264.00	2,216

Pierre Legault Buying and Selling Activity at Bicycle Therapeutics

Bicycle Therapeutics Company Overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Today's Range

Now: $22.52

$22.00

$22.70

50 Day Range

MA: $23.95

$21.82

$26.10

2 Week Range

Now: $22.52

$12.54

$28.91

Volume

117,997 shs

Average Volume

378,404 shs

Market Capitalization

$676.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89